Prior Authorization Form



Note: Please provide as much information as possible on this form. Missing data may cause processing delays for requested authorization(s). Attach additional sheets to this form if necessary.

Please fax the completed PA form and any additional informational sheets to Nirvanahealth at the following fax number: +1(866) 871-8565

Patient Information		Prescriber Information		
Patient Name:		Prescriber Name:		
Health Plan Name:		Prescriber Address:		
Patient Insurance Id:		_		
Patient Date of Birth:		Prescriber Phone: ()	
Patient Phone:		Prescriber Fax: ()	
		Prescriber Specialty:		
		Prescriber DEA:		
		Prescriber NPI:		
Medica	tion & M	edical Information		
	[] Symde		ng (night) tablets [] Symdeko 50 mg-75	
Requested Daily Quantity Limit – Amount:				
Requested Daily Quantity Limit – Days:				
Expected Length of Therapy:				
Directions:				
Diagnosis and Diagnosis Codes (ICD-10 Standard Codes):				
List drugs used previously to treat the same condition:				
Additional clinical information or history. Please include any relevant test results and/or medical record notes:				
Questionnaire				
Q1: I, as the provider or designated representative of the provider, certify and attest that the information provided is complete and accurate and that, upon request, I shall provide any information to RxAdvance that RxAdvance determines is reasonably necessary to verify my responses. (Check only one that apply)				
[] Yes				
[] No				
Q2: Is the member currently treated with this medication? (Check only one that apply)				
[] Yes (please list start date of therapy (month/day/year))(*Required)				
[] No				
Q3: What is the member diagnosis? (Check only one that apply)				

Prior Authorization Form



[] Cystic Fibrosis (CF)	
[] Other (please specify the member's diagnosis and provide clinical rationale for the req(*Required)	uest)
Q4: Does the member have documentation of positive clinical response to therapy (e.g., improdecreased number of pulmonary exacerbations)? (Check only one that apply)	ovement in lung function or
[] Yes (please provide documentation of positive clinical response)(*Required)	
[] No (please provide medical justification for continuation of therapy)(*Required)	
Q5: What is the member diagnosis? (Check only one that apply)	
[] Cystic Fibrosis (CF)	
[] Other (please specify the member's diagnosis and provide clinical rationale for the required)	uest)
Q6: Is the member homozygous for the F508del mutation in the CF transmembrane conductar detected by a U.S. Food and Drug Administration (FDA)-cleared cystic fibrosis mutation test or approved by Clinical Laboratory Improvement Amendments (CLIA)? (Check only one that appl	a test performed at a facility
[] Yes (please provide mutation type, date of test and the test type)(*Required)	
[] No	
Q7: Does the member have at least one mutation in the CFTR gene that is responsive to tezaca and/or clinical evidence as detected by a U.S. Food and Drug Administration (FDA)-cleared cyst performed at a facility approved by Clinical Laboratory Improvement Amendments (CLIA)? (Ch	tic fibrosis mutation test or a test
[] Yes (please provide mutation type, date of test and the test type)(*Required)	
[] No	
Q8: Is the member at least 6 years of age or older? (Check only one that apply)	
[] Yes	
[] No (please specify the member's age)	(*Required)
Q9: Is the requested medication prescribed by or in consultation with a pulmonologist or speci (Check only one that apply)	ialist affiliated with a CF care center?
[] Yes (please specofy prescriber specialty)	(*Required)
[] No (please provide clinical rationale for the request)(*Required)	
Attestation: I attest the information provided is true and accurate to the best of my knowledge. I unders Medical Group or its designated representatives may perform a routine audit and request the medical in accuracy of the information reported on this form.	
Signature of Prescriber or Authorized Representative:	ate:
Print Authorized Representative Name:	